Phase 2/3 Trial of AXS-05 for Alzheimer’s Agitation Enrolls First Patient

Phase 2/3 Trial of AXS-05 for Alzheimer’s Agitation Enrolls First Patient
Axsome Therapeutics has announced that the first patient was enrolled in the ADVANCE-1 Phase 2/3 trial evaluating the effectiveness and safety of its investigative therapy AXS-05 for the treatment of agitation in Alzheimer’s disease patients. Agitation is related to anxiety and is reported by nearly 50 percent of Alzheimer’s patients. It’s frequently used as an umbrella term to refer to

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

    • Tim Bossie says:

      Hi Maribeth… that is something that your doctor should be able to help you with. It will depend on a number of factors that they should know about.

Leave a Comment

Your email address will not be published. Required fields are marked *